{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:13:15Z","timestamp":1792811595231,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH020"],"award-info":[{"award-number":["ZR2021QH020"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH306"],"award-info":[{"award-number":["ZR2023QH306"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH293"],"award-info":[{"award-number":["ZR2024MH293"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303896"],"award-info":[{"award-number":["82303896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08444-7","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T13:06:35Z","timestamp":1751720795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer"],"prefix":"10.1038","volume":"8","author":[{"given":"Gonghua","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-1307","authenticated-orcid":false,"given":"Kai","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"8444_CR1","doi-asserted-by":"crossref","unstructured":"Bookman, M. Optimal primary therapy of ovarian cancer. Ann. Oncol. 27, i58-i62 (2016).","DOI":"10.1093\/annonc\/mdw088"},{"key":"8444_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719\u2013725 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"8444_CR3","unstructured":"Armstrong D, A. R. et al. Ovarian cancer, version 1. 2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw 22, 43\u201369 (2024)."},{"key":"8444_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"S Noordermeer","year":"2019","unstructured":"Noordermeer, S. & van Attikum, H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 29, 820\u2013834 (2019).","journal-title":"Trends Cell Biol."},{"key":"8444_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li, H. et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol. Cancer 19, 107 (2020).","journal-title":"Mol. Cancer"},{"key":"8444_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"8444_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","volume":"7","author":"K Fugger","year":"2021","unstructured":"Fugger, K., Hewitt, G., West, S. C. & Boulton, S. J. Tackling PARP inhibitor resistance. Trends Cancer 7, 1102\u20131118 (2021).","journal-title":"Trends Cancer"},{"key":"8444_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1146\/annurev-biochem-061611-090435","volume":"81","author":"X Liu","year":"2012","unstructured":"Liu, X. & Winey, M. The MPS1 family of protein kinases. Annu. Rev. Biochem. 81, 561\u2013585 (2012).","journal-title":"Annu. Rev. Biochem."},{"key":"8444_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cub.2005.01.010","volume":"15","author":"M Jones","year":"2005","unstructured":"Jones, M. et al. Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. Curr. Biol. CB 15, 160\u2013165 (2005).","journal-title":"Curr. Biol. CB"},{"key":"8444_CR10","doi-asserted-by":"publisher","first-page":"R966","DOI":"10.1016\/j.cub.2012.10.006","volume":"22","author":"P Lara-Gonzalez","year":"2012","unstructured":"Lara-Gonzalez, P., Westhorpe, F. & Taylor, S. The spindle assembly checkpoint. Curr. Biol. CB 22, R966\u2013R980 (2012).","journal-title":"Curr. Biol. CB"},{"key":"8444_CR11","doi-asserted-by":"publisher","first-page":"e0174863","DOI":"10.1371\/journal.pone.0174863","volume":"12","author":"J Stratford","year":"2017","unstructured":"Stratford, J. et al. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. PLoS ONE 12, e0174863 (2017).","journal-title":"PLoS ONE"},{"key":"8444_CR12","doi-asserted-by":"publisher","first-page":"e97739","DOI":"10.1371\/journal.pone.0097739","volume":"9","author":"X Liang","year":"2014","unstructured":"Liang, X. et al. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma. PLoS ONE 9, e97739 (2014).","journal-title":"PLoS ONE"},{"key":"8444_CR13","doi-asserted-by":"publisher","first-page":"34309","DOI":"10.18632\/oncotarget.5295","volume":"6","author":"X Liu","year":"2015","unstructured":"Liu, X., Liao, W., Yuan, Q., Ou, Y. & Huang, J. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. Oncotarget 6, 34309\u201334320 (2015).","journal-title":"Oncotarget"},{"key":"8444_CR14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.biopha.2016.08.004","volume":"83","author":"S Chen","year":"2016","unstructured":"Chen, S., Wang, Y., Ni, C., Meng, G. & Sheng, X. HLF\/miR-132\/TTK axis regulates cell proliferation, metastasis and radiosensitivity of glioma cells. Biomed. Pharmacother. 83, 898\u2013904 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"8444_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111669","volume":"385","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. Silencing TTK expression inhibits the proliferation and progression of prostate cancer. Exp. Cell Res. 385, 111669 (2019).","journal-title":"Exp. Cell Res."},{"key":"8444_CR16","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/2211-5463.12909","volume":"10","author":"H Huang","year":"2020","unstructured":"Huang, H., Yang, Y., Zhang, W., Liu, X. & Yang, G. TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt-mTOR pathway. FEBS Open Bio 10, 1542\u20131549 (2020).","journal-title":"FEBS Open Bio"},{"key":"8444_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12032-019-1320-y","volume":"37","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. Mitotic checkpoint kinase Mps1\/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKC\u03b1\/ERK1\/2 and PI3K\/Akt pathway. Med. Oncol. 37, 5 (2019).","journal-title":"Med. Oncol."},{"key":"8444_CR18","first-page":"4854","volume":"11","author":"F Chen","year":"2018","unstructured":"Chen, F. et al. Protein kinase TTK promotes proliferation and migration and mediates epithelial-mesenchymal transition in human bladder cancer cells. Int. J. Clin. Exp. Pathol. 11, 4854\u20134861 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"8444_CR19","unstructured":"Canadian Cancer Trials, G., Stand Up To, C., Canadian Breast Cancer, F. & Ontario Institute for Cancer, R. CFI-402257 in combination with paclitaxel in patients with advanced\/metastatic HER2-negative breast cancer (2021)."},{"key":"8444_CR20","unstructured":"Bayer. Phase I dose escalation of Oral BAY1161909 in combination with intravenous paclitaxel (2017)."},{"key":"8444_CR21","unstructured":"Bayer. Phase I study of oral BAY 1217389 in combination with intravenous paclitaxel (2018)."},{"key":"8444_CR22","unstructured":"Boston, P. Study of paclitaxel in combination with BOS172722 in patients with advanced nonhaematologic malignancies (2021)."},{"key":"8444_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1172\/JCI130435","volume":"130","author":"B Chandler","year":"2020","unstructured":"Chandler, B. et al. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.  J. Clin. Investig. 130, 958\u2013973 (2020).","journal-title":"J. Clin. Investig."},{"key":"8444_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbrc.2021.01.089","volume":"550","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21. Biochem. Biophys. Res. Commun. 550, 84\u201391 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"8444_CR25","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1093\/annonc\/mdv293","volume":"26","author":"A Maia","year":"2015","unstructured":"Maia, A. et al. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann. Oncol. 26, 2180\u20132192 (2015).","journal-title":"Ann. Oncol."},{"key":"8444_CR26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/1541-7786.MCR-14-0462-T","volume":"13","author":"UB Maachani","year":"2015","unstructured":"Maachani, U. B. et al. Targeting MPS1 enhances radiosensitization of human glioblastoma by modulating DNA repair proteins. Mol. Cancer Res. 13, 852\u2013862 (2015).","journal-title":"Mol. Cancer Res."},{"key":"8444_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41419-021-04429-6","volume":"12","author":"G Qi","year":"2021","unstructured":"Qi, G. et al. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR\/autophagy pathway. Cell Death Dis. 12, 1135 (2021).","journal-title":"Cell Death Dis."},{"key":"8444_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/carcin\/bgq035","volume":"31","author":"W Shi","year":"2010","unstructured":"Shi, W. et al. The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. Carcinogenesis 31, 994\u20131002 (2010).","journal-title":"Carcinogenesis"},{"key":"8444_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcdb.2018.04.005","volume":"86","author":"B Byrne","year":"2019","unstructured":"Byrne, B. & Oakley, G. Replication protein A, the laxative that keeps DNA regular: the importance of RPA phosphorylation in maintaining genome stability. Semin. Cell Dev. Biol. 86, 112\u2013120 (2019).","journal-title":"Semin. Cell Dev. Biol."},{"key":"8444_CR30","doi-asserted-by":"publisher","first-page":"12634","DOI":"10.1074\/jbc.272.19.12634","volume":"272","author":"H Niu","year":"1997","unstructured":"Niu, H. et al. Mapping of amino acid residues in the p34 subunit of human single-stranded DNA-binding protein phosphorylated by DNA-dependent protein kinase and Cdc2 kinase in vitro.  J. Biol. Chem. 272, 12634\u201312641 (1997).","journal-title":"J. Biol. Chem."},{"key":"8444_CR31","doi-asserted-by":"publisher","first-page":"23896","DOI":"10.1074\/jbc.272.38.23896","volume":"272","author":"M Zernik-Kobak","year":"1997","unstructured":"Zernik-Kobak, M., Vasunia, K., Connelly, M., Anderson, C. & Dixon, K. Sites of UV-induced phosphorylation of the p34 subunit of replication protein A from HeLa cells.  J. Biol. Chem. 272, 23896\u201323904 (1997).","journal-title":"J. Biol. Chem."},{"key":"8444_CR32","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1021\/bi0480584","volume":"44","author":"J Nuss","year":"2005","unstructured":"Nuss, J. et al. DNA damage induced hyperphosphorylation of replication protein A. 1. Identification of novel sites of phosphorylation in response to DNA damage. Biochemistry 44, 8428\u20138437 (2005).","journal-title":"Biochemistry"},{"key":"8444_CR33","doi-asserted-by":"publisher","first-page":"35910","DOI":"10.1074\/jbc.M704645200","volume":"282","author":"R Anantha","year":"2007","unstructured":"Anantha, R., Vassin, V. & Borowiec, J. Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair.  J. Biol. Chem. 282, 35910\u201335923 (2007).","journal-title":"J. Biol. Chem."},{"key":"8444_CR34","doi-asserted-by":"publisher","first-page":"32775","DOI":"10.1074\/jbc.M505705200","volume":"280","author":"Y Liu","year":"2005","unstructured":"Liu, Y., Kvaratskhelia, M., Hess, S., Qu, Y. & Zou, Y. Modulation of replication protein A function by its hyperphosphorylation-induced conformational change involving DNA binding domain B.  J. Biol. Chem. 280, 32775\u201332783 (2005).","journal-title":"J. Biol. Chem."},{"key":"8444_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1042\/BJ20050379","volume":"391","author":"X Wu","year":"2005","unstructured":"Wu, X., Yang, Z., Liu, Y. & Zou, Y. Preferential localization of hyperphosphorylated replication protein A to double-strand break repair and checkpoint complexes upon DNA damage.  Biochem. J. 391, 473\u2013480 (2005).","journal-title":"Biochem. J."},{"key":"8444_CR36","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-18-0618","volume":"78","author":"F B\u00e9langer","year":"2018","unstructured":"B\u00e9langer, F. et al. Replication protein A availability during DNA replication stress is a major determinant of cisplatin resistance in ovarian cancer cells. Cancer Res. 78, 5561\u20135573 (2018).","journal-title":"Cancer Res."},{"key":"8444_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/hed.21234","volume":"32","author":"K Manthey","year":"2010","unstructured":"Manthey, K., Glanzer, J., Dimitrova, D. & Oakley, G. Hyperphosphorylation of replication protein A in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines. Head. Neck 32, 636\u2013645 (2010).","journal-title":"Head. Neck"},{"key":"8444_CR38","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv https:\/\/doi.org\/10.1101\/2024.05.21.595159 (2024).","DOI":"10.1101\/2024.05.21.595159"},{"key":"8444_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13046-022-02570-4","volume":"41","author":"X Lu","year":"2022","unstructured":"Lu, X. et al. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. J. Exp. Clin. Cancer Res. 41, 355 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"8444_CR40","doi-asserted-by":"crossref","unstructured":"Gralewska, P. et al. PARP inhibition increases the reliance on ATR\/CHK1 checkpoint signaling leading to synthetic lethality-an alternative treatment strategy for epithelial ovarian cancer cells independent from HR effectiveness. Int. J. Mol. Sci. 21, 9715 (2020).","DOI":"10.3390\/ijms21249715"},{"key":"8444_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2016.07.088","volume":"143","author":"AJ Wilson","year":"2016","unstructured":"Wilson, A. J. et al. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. Gynecol. Oncol. 143, 143\u2013151 (2016).","journal-title":"Gynecol. Oncol."},{"key":"8444_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ygyno.2018.03.049","volume":"149","author":"AJ Wilson","year":"2018","unstructured":"Wilson, A. J., Stubbs, M., Liu, P., Ruggeri, B. & Khabele, D. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol. Oncol. 149, 575\u2013584 (2018).","journal-title":"Gynecol. Oncol."},{"key":"8444_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41420-021-00638-2","volume":"7","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors. Cell Death Discov. 7, 259 (2021).","journal-title":"Cell Death Discov."},{"key":"8444_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04670-7","volume":"13","author":"H Ma","year":"2022","unstructured":"Ma, H. et al. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer. Cell Death Dis. 13, 263 (2022).","journal-title":"Cell Death Dis."},{"key":"8444_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41420-025-02309-y","volume":"11","author":"K Teng","year":"2025","unstructured":"Teng, K., Ma, H., Gai, P., Zhao, X. & Qi, G. SPHK1 enhances olaparib resistance in ovarian cancer through the NFkappaB\/NRF2\/ferroptosis pathway. Cell Death Discov. 11, 29 (2025).","journal-title":"Cell Death Discov."},{"key":"8444_CR46","doi-asserted-by":"publisher","first-page":"7748","DOI":"10.1074\/jbc.M410152200","volume":"280","author":"J Wei","year":"2005","unstructured":"Wei, J. et al. TTK\/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68.  J. Biol. Chem. 280, 7748\u20137757 (2005).","journal-title":"J. Biol. Chem."},{"key":"8444_CR47","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/onc.2008.477","volume":"28","author":"Y Yeh","year":"2009","unstructured":"Yeh, Y., Huang, Y., Lin, T. & Shieh, S. The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK\/hMps1. Oncogene 28, 1366\u20131378 (2009).","journal-title":"Oncogene"},{"key":"8444_CR48","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/nar\/gkv1173","volume":"44","author":"Z Yu","year":"2016","unstructured":"Yu, Z., Huang, Y. & Shieh, S. Requirement for human Mps1\/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation. Nucleic Acids Res. 44, 1133\u20131150 (2016).","journal-title":"Nucleic Acids Res."},{"key":"8444_CR49","doi-asserted-by":"crossref","unstructured":"Meessen, S. et al. A comparative assessment of replication stress markers in the context of telomerase. Cancers 14, 2205 (2022).","DOI":"10.3390\/cancers14092205"},{"key":"8444_CR50","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.celrep.2013.04.018","volume":"3","author":"B Shiotani","year":"2013","unstructured":"Shiotani, B. et al. Two distinct modes of ATR activation orchestrated by Rad17 and Nbs1. Cell Rep. 3, 1651\u20131662 (2013).","journal-title":"Cell Rep."},{"key":"8444_CR51","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. 29, 2800\u20132807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"8444_CR52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nsmb.1769","volume":"17","author":"D Lee","year":"2010","unstructured":"Lee, D. et al. A PP4 phosphatase complex dephosphorylates RPA2 to facilitate DNA repair via homologous recombination. Nat. Struct. Mol. Biol. 17, 365\u2013372 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"8444_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jmb.2007.07.068","volume":"373","author":"K Sleeth","year":"2007","unstructured":"Sleeth, K. et al. RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. J. Mol. Biol. 373, 38\u201347 (2007).","journal-title":"J. Mol. Biol."},{"key":"8444_CR54","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","volume":"64","author":"H Wang","year":"2004","unstructured":"Wang, H., Wang, H., Powell, S. N., Iliakis, G. & Wang, Y. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res. 64, 7139\u20137143 (2004).","journal-title":"Cancer Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08444-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T14:02:53Z","timestamp":1751724173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08444-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8444"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08444-7","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods in this study were performed in accordance with the relevant guidelines and regulations. Ethics Committee at Qilu Hospital of Shandong University approved the study. The tumor formation assay was approved by the Shandong University Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors of the manuscript agree to article's publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"1011"}}